AlphAIAlphAI — Financial news for AI agents
MarketBeatMAR 93 min read$RFIL

RF Industries (RFIL) Expected to Announce Quarterly Earnings on Monday

RF Industries (NASDAQ: RFIL) is scheduled to release its Q1 2026 earnings after market close on Monday, March 16th, with analysts forecasting earnings of $0.03 per share and revenue of $18.72 million. The company previously beat estimates in Q4 2025, reporting $0.20 EPS against a $0.09 consensus. RFIL stock currently has a "Moderate Buy" rating from analysts with an average price target of $10.25, and institutional ownership stands at about 23.5%.

Original reporting
MarketBeat · MarketBeat
Published Mar 9, 2026, 6:52 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Mar 9, 2026, 8:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
RF Industries (RFIL) Expected to Announce Quarterly Earnings on Monday — source image
Source · MarketBeat
Decision brief

The 30-second read

$RFILNeutralMed
01

Why it matters

Earnings results could influence short-term trading strategies but are unlikely to cause long-term shifts unless accompanied by significant news or industry changes.

02

Market read

While the company operates in a niche market, its earnings release is relevant for traders focusing on the electronics sector and short-term market movements.

03

What to watch

Potential supply chain issues or macroeconomic factors could influence earnings beyond analyst forecasts, introducing additional risk.

Timing: High, as earnings are scheduled for March 16, 2026.

Background

RF Industries specializes in electronic interconnect solutions, serving various industrial and commercial markets.

Company-level read

Ticker impact

$RFILNeutralMedium confidence
Context

The upcoming earnings report is highly relevant for short-term traders and investors interested in RF Industries.

Expected impact

Potential slight upward movement post-earnings if results meet or exceed forecasts.

Evidence & confidence

The forecasted earnings are modest, and the previous beat suggests a cautious optimism. However, the low relevance score (1.0) indicates limited immediate impact on the broader market.

Market effects

Sector

The electronics and technology sectors may experience minor movements based on RF Industries' earnings, but no significant sector-wide shifts are expected.

Regional

Limited regional impact; primarily affecting investors and traders focused on US-based electronics firms.

Global

Low; RF Industries is a niche player with minimal influence on global markets.

Counterpoint

What could challenge this read

If earnings disappoint, the stock could decline by 5-10%, presenting a shorting opportunity for aggressive traders.

Key entities

  • Company
    RF Industries

    A manufacturer of electronic interconnect solutions.

Read at source← All news

Related articles

SEP 15
$SREHighAI 8/10

Sempra Locks In Petrobras for 20-Year U.S. LNG Supply Deal

Sempra Infrastructure signed a 20-year LNG supply deal with Petrobras for 800,000 tonnes per year, sourced from its Port Arthur LNG Phase 2 project in Texas. The agreement adds Petrobras as Sempra's first South American LNG customer. Port Arthur Phase 2, with a $14 billion estimated cost, is set to add 13 million tonnes per annum of liquefaction capacity and begin operations in 2030-2031. Sempra has previously secured LNG agreements with ConocoPhillips, JERA, and EQT for Phase 2.

oilprice.com2 min
SEP 15
$NVSLowAI 8/10

Back to Back Heart Drug Failures at Novartis and Novo Nordisk Undercut Two Leading Theories of Cardiovascular Risk

Novartis' pelacarsen and Novo Nordisk's ziltivekimab failed in Phase 3 trials, testing different cardiovascular risk theories. Both drugs did not reduce cardiovascular events despite lowering targets. Novartis reported pelacarsen's Lp(a)HORIZON trial results, while Novo Nordisk halted ziltivekimab's HERMES and ATHENA trials. Analysts estimated pelacarsen's peak sales at $4B-$6B. Both companies have other trials ongoing.

medicaldaily.com2 min